

# **Exhibit K**

**Sent:** 8/30/2023 3:39:39 PM  
**From:** Howard Hochster <hh458@cinj.rutgers.edu>  
**To:** "Karen J"  
**Cc:** "Patrick" , "Christian"  
**Bcc:**  
**Importance:** Normal  
**Subject:** Re: Time Sensitive! NRG-GI005 Interim Analysis and Dr-Pt Letters

---

It's a problem with the way that Guardant Lunar (Reveal) calls out the cancers. I have been skeptical.

We need a listing of all patients enrolled at all site and their arm assignment.

Then we can send out letters. Do we have anyone now on treatment at any site?

Also we need to handle this, not Cooperman. But we should send this notice as an FYI to any doc who enrolled patients in the system and tell them  
We will be notifying the patients.

HH

Howard S. Hochster, MD  
CINJ Associate Director, Clinical Research  
Director Clinical Oncology Research, RWJ-B Health System  
195 Little Albany Street, Room 2004  
New Brunswick, NJ 08903  
Tel 732-235-5912  
Fax 732-235-6797  
email: howard.hochster@rutgers.edu

Sent from my iPhone

On Aug 30, 2023, at 15:36, Karen J Jackson <jacksoka@cinj.rutgers.edu> wrote:

I will send it to Cooperman.

*Karen*

Karen Jackson  
Associate Director, Regulatory Affairs  
Rutgers Cancer Institute of New Jersey  
Email: [jacksoka@cinj.rutgers.edu](mailto:jacksoka@cinj.rutgers.edu)

Phone: 732-675-1055

*"Don't count the days, make the days count."~Muhammad Ali*

*To prevent inadvertent disclosure of personal health information, please do not include patient information in your email to regulatory.*

CONFIDENTIALITY NOTICE: This email communication may contain private, confidential, or legally privileged information intended for the sole use of the designated and/or duly authorized recipients(s). If you are not the intended recipient or have received this email in error, please notify the sender immediately by email and permanently delete all copies of this email including all attachments without reading them. If you are the intended recipient, secure the contents in a manner that conforms to all applicable state and/or federal requirements related to privacy and confidentiality of such information.

---

**From:** Patrick Boland <pb564@cinj.rutgers.edu>  
**Sent:** Wednesday, August 30, 2023 3:35 PM  
**To:** Karen J Jackson <jacksoka@cinj.rutgers.edu>; Howard Hochster <hh458@cinj.rutgers.edu>  
**Cc:** Christian Misdary <cm1344@cinj.rutgers.edu>  
**Subject:** RE: Time Sensitive! NRG-GI005 Interim Analysis and Dr-Pt Letters

Yes, I just pulled this up when I saw the NRG email. Thanks. Need to go through it and figure out which patients need to be contacted.

Bottom line, higher than anticipated false positive rate. I will share with the other med oncs here.... pending more granular data on false positive rate, etc...

Pat

---

**From:** Karen J Jackson <jacksoka@cinj.rutgers.edu>  
**Sent:** Wednesday, August 30, 2023 3:29 PM  
**To:** Patrick Boland <pb564@cinj.rutgers.edu>; Howard Hochster <hh458@cinj.rutgers.edu>  
**Cc:** Christian Misdary <cm1344@cinj.rutgers.edu>  
**Subject:** FW: Time Sensitive! NRG-GI005 Interim Analysis and Dr-Pt Letters  
**Importance:** High

Please see attached Dear Colleague letter from NRG.

*Karen*

Karen Jackson  
Associate Director, Regulatory Affairs  
Rutgers Cancer Institute of New Jersey  
Email: [jacksoka@cinj.rutgers.edu](mailto:jacksoka@cinj.rutgers.edu)  
Phone: 732-675-1055

*"Don't count the days, make the days count."~Muhammad Ali*

*To prevent inadvertent disclosure of personal health information, please do not include patient information in your email to regulatory.*

CONFIDENTIALITY NOTICE: This email communication may contain private, confidential, or legally privileged information intended for the sole use of the designated and/or duly authorized recipients(s). If you are not the intended recipient or have received this email in error, please notify the sender immediately by email and permanently delete all copies of this email including all attachments without reading them. If you are the intended recipient, secure the contents in a manner that conforms to all applicable state and/or federal requirements related to privacy and confidentiality of such information.

**From:** NRG Oncology <[nrg-broadcasts+nrgoncology.org@ccsend.com](mailto:nrg-broadcasts+nrgoncology.org@ccsend.com)>

**Sent:** Wednesday, August 30, 2023 3:20 PM

**To:** Karen J Jackson <[jacksoka@cinj.rutgers.edu](mailto:jacksoka@cinj.rutgers.edu)>

**Subject:** Time Sensitive! NRG-GI005 Interim Analysis and Dr-Pt Letters

NRG Oncology **eNews**



## NRG-GI005

Time Sensitive

August 30, 2023

**This information must be relayed to physicians and patients  
participating in NRG-GI005 as quickly as possible.**

After the NCI's review of planned interim analysis information for the phase II endpoint for NRG-GI005, the NCI has informed NRG Oncology that **physicians and patients must be informed of the outcome of the NCI's review.** Therefore, the following letters have been prepared to inform investigators and patients, and the letters are posted, along with this notice, to the GI005 page on the [CTSU website](#).

- Dear Doctor Letter, dated August 30, 2023
- Dear Patient Letter Template v.1.1 – **Treated**


*This letter **must** be given **as soon as possible** (within the next 30 days of this notice; by September 29) to patients who were randomized to Arm 2 and are currently receiving chemotherapy or have completed chemotherapy.*

- Dear Patient Letter Template v1.0 – **Non-treated**

*This letter **must** be given as soon as possible (within the next 3 months; by November 30) to patients who were randomized to Arm 1 and patients randomized to Arm 2 who did not receive chemotherapy.*

NRG Oncology has submitted these letters to the CIRB on behalf of participating NRG-GI005 sites; however, please note that **NCI has confirmed that because this is a safety issue, sites do not need to wait for CIRB review/approval to proceed with informing patients and assessing the willingness of patients to continue with the study and/or study-related treatment.**

If you have any questions regarding this information, please contact the Clinical Coordinating Department at 1-800-477-7227 or [ccdpg@nrgoncology.org](mailto:ccdpg@nrgoncology.org).



NRG Oncology | 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103

[Unsubscribe jacksoka@cinj.rutgers.edu](mailto:jacksoka@cinj.rutgers.edu)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by [nrg-broadcasts@nrgoncology.org](mailto:nrg-broadcasts@nrgoncology.org) powered by



[Try email marketing for free today!](#)